Literature DB >> 28419407

University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.

Natalie Galanina1, Sonali M Smith2, Chuanhong Liao2, Adam Petrich3, Bernadette Libao2, Ronald Gartenhaus4, Jason R Westin5, Kenneth S Cohen2, James A Knost6, Walter M Stadler2, Austin Doyle7, Theodore Karrison2, Leo I Gordon3, Andrew M Evens8.   

Abstract

Entities:  

Keywords:  MEK inhibition; novel therapies; relapsed/refractory DLBCL; selumetinib

Mesh：

Substances：

Year:  2017        PMID： 28419407      PMCID： PMC5785463          DOI： 10.1111/bjh.14544

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

Authors:  Bert H O'Neil; Laura W Goff; John Sae Wook Kauh; Jonathan R Strosberg; Tanios S Bekaii-Saab; Ruey-Min Lee; Aslamuzzaman Kazi; Dominic T Moore; Maria Learoyd; Richard M Lush; Said M Sebti; Daniel M Sullivan
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.

Authors:  Tanios Bekaii-Saab; Mitch A Phelps; Xiaobai Li; Motoyasu Saji; Laura Goff; John Sae Wook Kauh; Bert H O'Neil; Stephanie Balsom; Catherine Balint; Ryan Liersemann; Vasily V Vasko; Mark Bloomston; William Marsh; L Austin Doyle; Gilian Ellison; Michael Grever; Matthew D Ringel; Miguel A Villalona-Calero
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

Review 3.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

Authors:  F Chang; L S Steelman; J T Lee; J G Shelton; P M Navolanic; W L Blalock; R A Franklin; J A McCubrey
Journal:  Leukemia       Date:  2003-07       Impact factor: 11.528

4.  The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.

Authors:  Savita Bhalla; Andrew M Evens; Bojie Dai; Sheila Prachand; Leo I Gordon; Ronald B Gartenhaus
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

5.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

6.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

Review 7.  Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy.

Authors:  Paul Shapiro
Journal:  Crit Rev Clin Lab Sci       Date:  2002-09       Impact factor: 6.250

8.  Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies.

Authors:  Bo Shi; Hsin-Ling Hsu; Andy M Evens; Leo I Gordon; Ronald B Gartenhaus
Journal:  Blood       Date:  2003-03-13       Impact factor: 22.113

9.  Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

Authors:  Alex A Adjei; Roger B Cohen; Wilbur Franklin; Clive Morris; David Wilson; Julian R Molina; Lorelei J Hanson; Lia Gore; Laura Chow; Stephen Leong; Lara Maloney; Gilad Gordon; Heidi Simmons; Allison Marlow; Kevin Litwiler; Suzy Brown; Gregory Poch; Katie Kane; Jerry Haney; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2008-04-07       Impact factor: 44.544
  9 in total
  3 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib.

Authors:  Olivia Campagne; Kee Kiat Yeo; Jason Fangusaro; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2020-12-23       Impact factor: 6.447

Review 2.  Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.

Authors:  Inna Serganova; Sanjukta Chakraborty; Samuel Yamshon; Yusuke Isshiki; Ryan Bucktrout; Ari Melnick; Wendy Béguelin; Roberta Zappasodi
Journal:  Front Cell Dev Biol       Date:  2022-01-07

Review 3.  KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders.

Authors:  Elena Vendramini; Riccardo Bomben; Federico Pozzo; Tamara Bittolo; Erika Tissino; Valter Gattei; Antonella Zucchetto
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.